Cytena: BICO's Cytena launches C.Station automated cell line development platform for antibody and gene therapies

BICO Group subsidiary Cytena today announced the launch of its C.Station platform for automating the development of stable cell lines. Cytena said in a news release that C.Station is a user-friendly platform that covers the entire cell line development workflow, from single-cell cloning of transfected cells to the selection of high-producing clones and upscaling. Cytena...The post BICO's Cytena launches C.Station automated cell line development platform for antibody and gene therapies appeared first on Medical Design and Outsourcing.